HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for PDS Biotechnology, maintaining a price target of $21. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential.
October 02, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for PDS Biotechnology, maintaining a price target of $21. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential.
The reiteration of a Buy rating and maintenance of a $21 price target by a reputable analyst suggests positive sentiment and potential upside for PDS Biotechnology. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100